Glucagon-like peptide-1 (GLP-1) receptor agonists, originally designed to help people with type 2 diabetes control blood sugar, are now proving effective for treating liver disease, chronic kidney disease, and obstructive sleep apnea. What started as a diabetes medication class has evolved into one of modern medicine's most versatile drug categories, with clinical evidence expanding faster than many healthcare providers can track.

How Are GLP-1 Drugs Being Used Beyond Diabetes?

At the 2026 American Pharmacists Association Annual Meeting in Los Angeles, pharmacy experts presented the latest evidence on GLP-1 therapies across multiple disease areas. The findings reveal that these medications address underlying metabolic problems in ways that extend far beyond blood sugar control.

• Liver Disease: In a phase 3 clinical trial called ESSENCE, semaglutide at 2.4 mg produced resolution of steatohepatitis (a serious liver condition) without worsening scarring in 62.9% of patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced fibrosis, compared to 34.3% with placebo. The FDA granted accelerated approval for this indication in August 2025, and the 2026 American Diabetes Association Standards of Care now recommend GLP-1 receptor agonists as preferred agents for patients with type 2 diabetes and biopsy-proven MASH or high fibrosis risk.
• Chronic Kidney Disease: In the phase 3 FLOW trial, semaglutide at 1 mg reduced the risk of major kidney events by 24% in patients with type 2 diabetes and chronic kidney disease (CKD), while also slowing the annual decline in kidney function. This finding resulted in a dedicated FDA indication for semaglutide in this population.
• Obstructive Sleep Apnea: Tirzepatide, a related GLP-1 medication, demonstrated a reduction of 25.3 to 29.3 breathing events per hour in the apnea-hypopnea index (a measure of sleep apnea severity) compared to approximately 5 with placebo, alongside 17% to 20% body weight reduction. Tirzepatide is the only GLP-1 medication with an FDA indication specifically for obstructive sleep apnea.

What Makes These Results Surprising to Doctors?

The expansion of GLP-1 therapies into kidney and liver disease represents a fundamental shift in how physicians understand these medications. Historically, doctors relied on a different drug class called SGLT2 inhibitors for kidney protection in diabetes patients. The new evidence suggests GLP-1 drugs now offer comparable or complementary benefits.

"I used to tell students: kidneys, that's the difference between an SGLT2 and a GLP-1. And now that's not even the difference anymore," said Emily Eddy, PharmD, associate professor of pharmacy practice and director of clinical services at Ohio Northern University.

Emily Eddy, PharmD, Associate Professor of Pharmacy Practice at Ohio Northern University

For liver disease, the clinical significance goes beyond simply preventing further damage. In the ESSENCE trial, semaglutide achieved actual resolution of steatohepatitis and reduction of fibrosis (scarring), not merely halting disease progression. This represents genuine improvement in key markers of liver damage, a finding that surprised many clinicians.

Are There Other Emerging Uses Being Studied?

Beyond the FDA-approved indications, researchers are investigating GLP-1 therapies for additional conditions. Early evidence suggests potential benefits in alcohol use disorder, though experts emphasize that this research remains preliminary and does not yet support routine clinical use. A large observational study of more than 120 million patients found that tirzepatide was associated with a significant reduction in alcohol use disorder incidence compared to other diabetes medications, with similar signals observed for semaglutide and liraglutide.

The proposed mechanism involves GLP-1 receptor expression in reward-related brain regions, which may dampen dopamine signaling associated with substance use. However, pharmacists and physicians stress that current evidence does not justify prescribing these medications for substance use disorder outside of clinical trials.

What's Changing in the GLP-1 Drug Pipeline?

The landscape of available GLP-1 medications is expanding rapidly. New formulations and drug combinations are entering the market or awaiting FDA approval, offering patients more options for convenience and effectiveness. Oral semaglutide at 25 mg, available since January 2026, uses a technology called salcaprozate sodium to improve absorption and eliminate the fasting requirements of earlier oral GLP-1 options. In the phase 3 OASIS 4 trial, the 25-mg tablet delivered a mean weight loss of 13.6% in patients with obesity and without diabetes, with 79.2% of participants achieving at least 5% weight loss compared to 31.1% with placebo.

Orforglipron, a first-in-class oral, small-molecule GLP-1 receptor agonist awaiting FDA action, carries no fasting or water restrictions, a meaningful practical advantage for patients. In the phase 3 ACHIEVE-3 head-to-head trial, orforglipron was noninferior and, for the highest dose, superior to oral semaglutide in hemoglobin A1C (a measure of average blood sugar over three months) reduction in patients with type 2 diabetes.

Additional medications in development include cagrilintide combined with semaglutide, which showed approximately 20.4% weight loss in the phase 3 REDEFINE-1 trial with a new drug application submitted in December 2025; maridebart cafraglutide, a once-monthly injectable showing 12.3% to 16.2% weight loss in phase 2 testing; and retatrutide, a triple agonist (targeting three different hormone pathways) showing up to 28.7% weight loss in the phase 3 TRIUMPH-4 trial.

Experts note that longer-acting or oral options could benefit specific patient populations, particularly those who struggle with weekly injection adherence. Monthly injectables may appeal especially to patients who find frequent injections burdensome.

Why Should Patients and Doctors Care About These Developments?

The expansion of GLP-1 therapies into liver, kidney, and sleep apnea treatment represents a significant shift in how doctors approach metabolic disease. Rather than treating diabetes as an isolated condition, clinicians can now address the underlying metabolic dysfunction that contributes to multiple organ systems. For patients with type 2 diabetes who also have liver disease, kidney disease, or sleep apnea, a single medication class may now offer benefits across multiple conditions.

Pharmacists play a crucial role in helping patients and providers navigate the distinction between FDA-approved uses and emerging evidence. As the evidence base continues to expand, healthcare providers must distinguish between findings that warrant clinical recommendations and those that remain preliminary. The rapid pace of new approvals and pipeline developments means that staying informed about GLP-1 therapies is increasingly important for anyone involved in diabetes care or metabolic disease management.